[go: up one dir, main page]

BRPI0923786C8 - compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos - Google Patents

compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos

Info

Publication number
BRPI0923786C8
BRPI0923786C8 BRPI0923786A BRPI0923786A BRPI0923786C8 BR PI0923786 C8 BRPI0923786 C8 BR PI0923786C8 BR PI0923786 A BRPI0923786 A BR PI0923786A BR PI0923786 A BRPI0923786 A BR PI0923786A BR PI0923786 C8 BRPI0923786 C8 BR PI0923786C8
Authority
BR
Brazil
Prior art keywords
compounds
phenylbenzo
dihydro
pharmaceutical compositions
isoquinoline
Prior art date
Application number
BRPI0923786A
Other languages
English (en)
Inventor
Vensel David
Kelleher Eugene
Wu Hui
Lapierre Jean-Marc
Tandon Manish
Ashwell Mark
Westlund Neil
Namdev Nivedita
Palma Rocio
Yang Rui-Yang
Eathiraj Sudharshan
M Ali Syed
Liu Yanbin
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of BRPI0923786A2 publication Critical patent/BRPI0923786A2/pt
Publication of BRPI0923786B1 publication Critical patent/BRPI0923786B1/pt
Publication of BRPI0923786C1 publication Critical patent/BRPI0923786C1/pt
Publication of BRPI0923786C8 publication Critical patent/BRPI0923786C8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/54—1,3-Diazines; Hydrogenated 1,3-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos. a presente invenção refere-se a compostos 5,6-dihidro-6-fenilbenzo [f] isoquinolin-2-amina substituídos e aos métodos de sintetizar esses compostos. a presente invenção também se relaciona com composições farmacêuticas contendo compostos 5,6-dihidro-6-fenilbenzo [f] isoquinolin-2-amina substituídos e métodos de tratamento de distúrbios de proliferação celular, tais como câncer, pela administração desses compostos e composições farmacêuticas a indivíduos em necessidade do mesmo.
BRPI0923786A 2008-12-30 2009-12-30 compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos BRPI0923786C8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14143908P 2008-12-30 2008-12-30
US61/141.439 2008-12-30
US26050509P 2009-11-12 2009-11-12
US61/260.505 2009-11-12
PCT/US2009/069813 WO2010078421A1 (en) 2008-12-30 2009-12-30 Substituted 5,6-dihydro-6-phenylbenzo[f] isoquinolin-2-amine compounds

Publications (4)

Publication Number Publication Date
BRPI0923786A2 BRPI0923786A2 (pt) 2016-07-26
BRPI0923786B1 BRPI0923786B1 (pt) 2020-11-24
BRPI0923786C1 BRPI0923786C1 (pt) 2021-05-11
BRPI0923786C8 true BRPI0923786C8 (pt) 2021-05-25

Family

ID=41682678

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923786A BRPI0923786C8 (pt) 2008-12-30 2009-12-30 compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos

Country Status (14)

Country Link
US (1) US8357694B2 (pt)
EP (1) EP2379506B1 (pt)
JP (1) JP5739820B2 (pt)
KR (1) KR101714799B1 (pt)
CN (1) CN102325755B (pt)
BR (1) BRPI0923786C8 (pt)
CA (1) CA2748491C (pt)
DK (1) DK2379506T3 (pt)
ES (1) ES2554623T3 (pt)
IL (1) IL213787A (pt)
MX (1) MX2011006959A (pt)
TW (1) TWI461410B (pt)
WO (1) WO2010078421A1 (pt)
ZA (1) ZA201104706B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013012681A1 (en) * 2011-07-15 2013-01-24 Abbott Laboratories Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
GB2499666A (en) * 2012-02-27 2013-08-28 Nanyang Polytechnic Mcl-1 inhibitors for the treatment of conditions associated with proliferative disorders
SI2861595T1 (sl) 2012-06-13 2017-04-26 Incyte Holdings Corporation Substituirane triciklične spojine kot inhibitorji fgfr
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
ES2657451T3 (es) 2013-04-19 2018-03-05 Incyte Holdings Corporation Heterocíclicos bicíclicos como inhibidores del FGFR
SG11201700703XA (en) 2014-08-18 2017-03-30 Eisai R&D Man Co Ltd Salt of monocyclic pyridine derivative and crystal thereof
BR112017004459A2 (pt) * 2014-09-05 2017-12-05 Arqule Inc composições e métodos para o tratamento de distúrbios de proliferação
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
SG10201913213WA (en) 2015-12-17 2020-03-30 Eisai R&D Man Co Ltd Therapeutic agent for breast cancer
WO2017106639A1 (en) * 2015-12-17 2017-06-22 Arqule, Inc. Methods for preparing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine
SG11201804670PA (en) 2015-12-17 2018-07-30 Arqule Inc Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3777860A4 (en) 2018-03-28 2021-12-15 Eisai R&D Management Co., Ltd. THERAPEUTIC FOR HEPATOCELLULAR CARCINOMA
KR20210018265A (ko) 2018-05-04 2021-02-17 인사이트 코포레이션 Fgfr 억제제의 고체 형태 및 이의 제조 방법
MX2020011639A (es) 2018-05-04 2021-02-15 Incyte Corp Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
KR20210066839A (ko) * 2018-09-27 2021-06-07 베타 파머수티컬 컴퍼니 리미티드 Fgfr4 저해제 및 그것의 용도
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7675711B2 (ja) 2019-10-14 2025-05-13 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220285A (es) 2019-12-04 2022-10-27 Incyte Corp Derivados de un inhibidor de fgfr
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN116547280A (zh) * 2020-10-08 2023-08-04 雷多纳治疗公司 用于治疗癌症的苯并[h]喹唑啉-4-胺和噻吩并[3,2-h]喹唑啉-4-胺衍生物
US20230416271A1 (en) * 2020-11-26 2023-12-28 Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd. Heteroarylquinazoline compounds as protein kinase inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN113354630B (zh) * 2021-06-30 2022-11-01 江南大学 一种5,6-二氢苯并[h]喹唑啉类化合物及其应用
TW202334097A (zh) * 2021-10-25 2023-09-01 美商雷度納製藥公司 用於治療癌症之苯并【ｈ】喹唑啉－４－胺衍生物
WO2023196629A1 (en) * 2022-04-07 2023-10-12 Redona Therapeutics, Inc. Benzo[h]quinazoline-4-amine derivatives for the treatment of cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623846A1 (de) 1976-05-28 1977-12-15 Hoechst Ag 4-chinazolinyl-guanidine und verfahren zu ihrer herstellung
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1154024B (it) 1982-09-22 1987-01-21 Lepetit Spa Derivati pridinici e procedimento per la loro produzione
US4814335A (en) 1982-12-30 1989-03-21 Biomeasure, Incorporated Antiviral compounds
US4625026A (en) 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
DD240010A1 (de) 1985-03-22 1986-10-15 Univ Berlin Humboldt Verfahren zur herstellung von substituierten 2-imino-1h-pyridin-1-aminen
SU1540240A1 (ru) 1988-05-16 1995-09-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 5-ЗАМЕЩЕННЫЕ 1-АМИНО -8,9-ДИГИДРО -8,8-ДИМЕТИЛ-3, 6Н- ПИРАЗОЛО [3,4-B] ПИРАНО[[4′,3′-d]] ПИРИДИНА ИЛИ ИХ ГИДРОХЛОРИДЫ, ОБЛАДАЮЩИЕ ПРОТИВОСУДОРОЖНОЙ АКТИВНОСТЬЮ
DD280109A1 (de) 1989-02-22 1990-06-27 Univ Berlin Humboldt Verfahren zur herstellung substituierter 1.2.4-triazolo/1.5-a/-pyridine
SU1626648A1 (ru) 1989-07-20 1995-09-27 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 1-амино-8,9- дигидро-5,8,8- триметил-3,6н- пиразоло[3,4-b] тиопирано [4,3-d]пиридин или его гидрохлорид, обладающие противосудорожной активностью
DE4117802A1 (de) 1991-05-30 1992-12-03 Berlin Chemie Ag 2-aminopyridin-3-carbonitrile als selektive hemmstoffe des humanen cytomegalievirus
AU7831694A (en) 1993-09-24 1995-04-10 Du Pont Merck Pharmaceutical Company, The Improved methods for preparing bis-imide compounds
US6046206A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
WO1997012880A1 (en) * 1995-10-02 1997-04-10 F.Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c-receptor antagonists
WO1998028281A1 (en) * 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
US6191123B1 (en) 1999-03-19 2001-02-20 Parker Hughes Institute Organic-arsenic compounds
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
RU2268260C2 (ru) 2000-03-31 2006-01-20 Ниппон Синяку Ко., Лтд. Производные хиназолина или хинолина и лекарственные средства на их основе
EP1371376A4 (en) 2001-03-19 2009-03-25 Nippon Shinyaku Co Ltd Antipruritic agents
WO2005014727A1 (en) 2003-07-17 2005-02-17 Ciba Specialty Chemicals Holding Inc. Black pigment compositions
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
DE602004032465D1 (de) 2003-12-02 2011-06-09 Teva Pharma Referenzstandard zur charakterisierung von rosuvastatin
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
DE502005008916D1 (de) 2004-07-23 2010-03-11 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
CA2599611C (en) 2005-02-09 2013-07-30 Chiang J. Li Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
CA2619992A1 (en) 2005-08-24 2007-03-01 Protherics Medicines Development Limited Cleavage of antifolate compounds
CN101421268B (zh) 2006-02-15 2016-01-06 Abbvie公司 作为有效parp抑制剂的吡唑并喹诺酮
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
AU2007342007A1 (en) 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as Axl inhibitors

Also Published As

Publication number Publication date
BRPI0923786B1 (pt) 2020-11-24
CN102325755B (zh) 2015-07-01
KR101714799B1 (ko) 2017-03-09
AU2009335010A8 (en) 2011-08-11
JP2012514045A (ja) 2012-06-21
ZA201104706B (en) 2012-08-29
TW201035055A (en) 2010-10-01
ES2554623T3 (es) 2015-12-22
EP2379506A1 (en) 2011-10-26
MX2011006959A (es) 2011-12-06
BRPI0923786C1 (pt) 2021-05-11
US20100239525A1 (en) 2010-09-23
IL213787A0 (en) 2011-07-31
US8357694B2 (en) 2013-01-22
WO2010078421A8 (en) 2011-10-27
CA2748491C (en) 2019-08-06
CA2748491A1 (en) 2010-07-08
JP5739820B2 (ja) 2015-06-24
BRPI0923786A2 (pt) 2016-07-26
TWI461410B (zh) 2014-11-21
EP2379506B1 (en) 2015-09-02
DK2379506T3 (en) 2015-12-14
WO2010078421A1 (en) 2010-07-08
IL213787A (en) 2014-08-31
CN102325755A (zh) 2012-01-18
AU2009335010A1 (en) 2011-07-21
KR20110099790A (ko) 2011-09-08

Similar Documents

Publication Publication Date Title
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12012501337A1 (en) Substituted pyrrolo-aminopyrimidine compounds
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
EA201001639A1 (ru) Композиции и способы их получения и применения
EP1893196A4 (en) DIARYLHYDANTOIN CONNECTIONS
MY176944A (en) Substituted pyrimidines for the treatment of diseases such as cancer
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
MX2009004435A (es) Tinturas dispersas, su preparacion y su uso.
UA107783C2 (en) Isoindoline compounds for use in treating cancer
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
SV2010003463A (es) Compuestos organicos
MX2011009780A (es) Pirimidinas sustituidas para el tratamiento del cancer.
WO2011082266A3 (en) Substituted heterocyclic compounds
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
PH12012501556A1 (en) Substituted naphthalenyl-pyrimidine compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2603 DE 24/11/2020 QUANTO AO ENDERECO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF